Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART C

Largest randomized trial of DynamX Bioadaptor to date with 2,400 patients enrolled, covering real-world population

Related Keywords

Sweden , Uppsala , Uppsala Lan , Motasim Sirhan , Stefan James , David Erlinge , Lund University , Uppsala University Hospital , Swedeheart Steering Committee , Elixir Medical , Dynamx Coronary Bioadaptor System , Resolute Onyx Drug Eluting Stent , Dynamx Bioadaptor , Resolute Onyx , Device Oriented Clinical Endpoint , Professor David Erlinge , Professor Stefan James , Swedeheart Steering ,